Major trial aims to redefine First-Line treatment for blood cancer
NCT ID NCT07428369
Summary
This study is testing a new drug combination (linvoseltamab, bortezomib, lenalidomide) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. It will compare this new combination, with and without the transplant, to the current standard treatment. The main goals are to see if the new treatment works better and if it can eliminate the need for a stem cell transplant as part of initial therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.